Vaxcyte Inc
PCVX47.650USD
-0.160-0.33%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
6.20BMarket Cap
LossP/E TTM
More Details of Vaxcyte Inc Company
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Vaxcyte Inc Info
Ticker SymbolPCVX
Company nameVaxcyte Inc
IPO dateJun 12, 2020
CEOPickering (Grant E)
Number of employees414
Security typeOrdinary Share
Fiscal year-endJun 12
Address825 Industrial Road, Ste. 300
CitySAN CARLOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94070
Phone16508370111
Websitehttps://vaxcyte.com/
Ticker SymbolPCVX
IPO dateJun 12, 2020
CEOPickering (Grant E)
Company Executives of Vaxcyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
658.46K
-2.69%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
75.59K
-9.54%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-20.53%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.01%
The Vanguard Group, Inc.
9.39%
RA Capital Management, LP
9.14%
Fidelity Management & Research Company LLC
7.90%
BlackRock Institutional Trust Company, N.A.
6.41%
Other
57.15%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.01%
The Vanguard Group, Inc.
9.39%
RA Capital Management, LP
9.14%
Fidelity Management & Research Company LLC
7.90%
BlackRock Institutional Trust Company, N.A.
6.41%
Other
57.15%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.44%
Investment Advisor/Hedge Fund
31.40%
Hedge Fund
19.35%
Venture Capital
11.37%
Research Firm
2.23%
Bank and Trust
0.97%
Sovereign Wealth Fund
0.75%
Individual Investor
0.68%
Pension Fund
0.61%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
14.69M
11.32%
+151.06K
+1.04%
Jun 30, 2025
The Vanguard Group, Inc.
11.97M
9.22%
-48.12K
-0.40%
Jun 30, 2025
RA Capital Management, LP
11.97M
9.22%
-223.16K
-1.83%
Jun 30, 2025
Fidelity Management & Research Company LLC
10.05M
7.74%
-677.06K
-6.31%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.05M
6.97%
-85.53K
-0.94%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.00M
4.62%
+3.30M
+122.04%
Jun 30, 2025
Wellington Management Company, LLP
4.95M
3.82%
-1.46M
-22.79%
Jun 30, 2025
State Street Investment Management (US)
4.94M
3.81%
+534.55K
+12.13%
Jun 30, 2025
D. E. Shaw & Co., L.P.
3.09M
2.38%
+2.22M
+255.86%
Jun 30, 2025
Paradigm BioCapital Advisors LP
3.37M
2.6%
+1.68M
+98.81%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.39%
State Street SPDR S&P Biotech ETF
1.65%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.5%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
iShares Russell 2000 Value ETF
0.34%
View more
Harbor Health Care ETF
Proportion4.32%
ALPS Medical Breakthroughs ETF
Proportion2.39%
State Street SPDR S&P Biotech ETF
Proportion1.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
ProShares Ultra Nasdaq Biotechnology
Proportion0.58%
Invesco Nasdaq Biotechnology ETF
Proportion0.57%
iShares Biotechnology ETF
Proportion0.5%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.44%
iShares Russell 2000 Value ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vaxcyte Inc?
The top five shareholders of Vaxcyte Inc are:
Janus Henderson Investors holds 14.69M shares, accounting for 11.32% of the total shares.
The Vanguard Group, Inc. holds 11.97M shares, accounting for 9.22% of the total shares.
RA Capital Management, LP holds 11.97M shares, accounting for 9.22% of the total shares.
Fidelity Management & Research Company LLC holds 10.05M shares, accounting for 7.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.05M shares, accounting for 6.97% of the total shares.
Janus Henderson Investors holds 14.69M shares, accounting for 11.32% of the total shares.
The Vanguard Group, Inc. holds 11.97M shares, accounting for 9.22% of the total shares.
RA Capital Management, LP holds 11.97M shares, accounting for 9.22% of the total shares.
Fidelity Management & Research Company LLC holds 10.05M shares, accounting for 7.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.05M shares, accounting for 6.97% of the total shares.
What are the top three shareholder types of Vaxcyte Inc?
The top three shareholder types of Vaxcyte Inc are:
Janus Henderson Investors
The Vanguard Group, Inc.
RA Capital Management, LP
Janus Henderson Investors
The Vanguard Group, Inc.
RA Capital Management, LP
How many institutions hold shares of Vaxcyte Inc (PCVX)?
As of 2025Q3, 668 institutions hold shares of Vaxcyte Inc, with a combined market value of approximately 148.53M, accounting for 114.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.88%.
What is the biggest source of revenue for Vaxcyte Inc?
In --, the -- business generated the highest revenue for Vaxcyte Inc, amounting to -- and accounting for --% of total revenue.
